Xvivo Perfusion AB (publ) (XVIPY)
OTCMKTS · Delayed Price · Currency is USD
4.600
+0.350 (8.24%)
Nov 24, 2025, 4:00 PM EST
Xvivo Perfusion AB Market Cap
Xvivo Perfusion AB has a market cap or net worth of $621.03 million as of November 26, 2025. Its market cap has decreased by -53.88% in one year.
Market Cap
621.03M
Enterprise Value
604.63M
Revenue
86.34M
Ranking
n/a
PE Ratio
195.71
Stock Price
$4.60
Market Cap Chart
Since October 8, 2012, Xvivo Perfusion AB's market cap has increased from 56.07M to 621.03M, an increase of 1,007.58%. That is a compound annual growth rate of 20.07%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Nov 27, 2025 | 621.03M | -55.47% |
| Dec 30, 2024 | 1.39B | 35.52% |
| Dec 29, 2023 | 1.03B | 96.50% |
| Dec 30, 2022 | 523.72M | -42.34% |
| Dec 30, 2021 | 908.22M | -17.47% |
| Dec 30, 2020 | 1.10B | 126.83% |
| Dec 30, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 28, 2018 | Upgrade Pro | Upgrade Pro |
| Dec 29, 2017 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2016 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2015 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Veradigm | 841.29M |
| Elite Pharmaceuticals | 572.12M |
| Glass House Brands | 507.44M |
| CytoDyn | 435.49M |
| Northwest Biotherapeutics | 391.33M |
| American Oncology Network | 346.66M |
| Silence Therapeutics | 299.94M |
| Nika Pharmaceuticals | 259.96M |